Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2-metastatic breast cancer treated with CDK4/6 inhibitors

被引：0
|
作者：
Antras, Jesus Fuentes
El Ghamrasni, Samah
Zou, Jinfeng
Dou, Aaron
Elliott, Mitchell J.
Avery, Lisa
Bratman, Scott Victor
Cescon, David W.
Bedard, Philippe L.
机构：
[1] Univ Hlth Network, Div Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Univ Toronto, Univ Hlth Network, Dept Biostat, Toronto, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1075
引用
收藏
页数：1
相关论文
共 50 条
  • [1] HEALTHCARE COSTS IN WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH CDK4/6 INHIBITORS
    Burne, R.
    Balu, S.
    Guerin, A.
    Liang, Y.
    Schloessmann, R.
    Bungay, R.
    Paul, M. L.
    VALUE IN HEALTH, 2020, 23 : S44 - S44
  • [2] HR+/HER2-metastatic Breast Cancer Increasing Data Density of CDK4/6 Inhibitors
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (09) : 485 - 485
  • [3] Clinical outcomes of treatment with CDK4/6 inhibitors in metastatic breast cancer among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2
    Scheel, R.
    Choong, G. M.
    Koch, R.
    Yadav, S. K.
    Karki, A.
    Rao, R.
    Boddicker, N. J.
    Hu, C.
    Na, J.
    Kaggal, V.
    Murphy, S.
    Giridhar, K. V.
    Yasir, S.
    Goetz, M. P.
    Couch, F. J.
    Yadav, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S364 - S364
  • [4] Breast Cancer CDK4/6 Inhibitors in Patients with metastatic HR+/HER2-Breast Cancer
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
  • [5] How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
    Cogliati, Viola
    Capici, Serena
    Pepe, Francesca Fulvia
    di Mauro, Pierluigi
    Riva, Francesca
    Cicchiello, Federica
    Maggioni, Claudia
    Cordani, Nicoletta
    Cerrito, Maria Grazia
    Cazzaniga, Marina Elena
    LIFE-BASEL, 2022, 12 (03):
  • [6] Real-world experience with CDK4/6 inhibitors for HR+/HER2-metastatic breast cancer (MBC)
    Abdallah, H. M. A.
    Owoseni, Y. I.
    Sultan, A.
    Ahmed, S.
    Wood, J.
    Varadhan, B.
    Ayodele, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S369 - S370
  • [7] Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2-metastatic breast cancer: A machine learning approach
    Moiso, Enrico
    Ferraro, Emanuela
    Cabel, Luc
    Safonov, Anton
    Ahmed, Mehnaj
    An, Julia Ah-Reum
    Jhaveri, Komal L.
    Norton, Larry
    Robson, Mark E.
    Modi, Shanu
    Chandarlapaty, Sarat
    Razavi, Pedram
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2-metastatic breast cancer in the United States
    Goyal, Ravi K.
    Holmes, Holly M.
    Chen, Hua
    Abughosh, Susan
    Candrilli, Sean D.
    Johnson, Michael L.
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 198 (01) : 159 - 166
  • [9] Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2-metastatic breast cancer
    Zagami, Paola
    Esposito, Angela
    Salimbeni, Beatrice Taurelli
    Giachetti, Pier Paolo Maria Berton
    Scafetta, Roberta
    Lambertini, Matteo
    Di Maio, Massimo
    Curigliano, Giuseppe
    Criscitiello, Carmen
    Cinieri, Saverio
    BREAST, 2025, 79
  • [10] Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2-Breast Cancer
    Weiss, Jennifer
    Afghahi, Anosheh
    Shagisultanova, Elena
    Diamond, Jennifer R.
    ONCOLOGY-NEW YORK, 2018, 32 (10): : 513 - 515
12345